Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SRRK, ALMS, MLYS, SEPN, Alamar Biosciences, and represent 73.02% of Samsara BioCapital's stock portfolio.
- Added to shares of these 6 stocks: Alamar Biosciences (+$67M), Parabilis Medicines (+$15M), ARTV (+$9.3M), Eloxx Pharmaceuticals (+$5.6M), IVA, RANI.
- Started 4 new stock positions in Parabilis Medicines, Alamar Biosciences, Eloxx Pharmaceuticals, ARTV.
- Reduced shares in these 7 stocks: ACLX (-$7.0M), JBIO (-$5.2M), PVLA, UPB, XFOR, KLRS, ABVX.
- Sold out of its positions in ACLX, PVLA.
- Samsara BioCapital was a net buyer of stock by $81M.
- Samsara BioCapital has $1.2B in assets under management (AUM), dropping by 18.30%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 24 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Scholar Rock Hldg Corp (SRRK) | 31.2 | $379M | 6.9M | 55.00 |
|
|
| Alumis (ALMS) | 14.7 | $179M | 6.3M | 28.14 |
|
|
| Mineralys Therapeutics (MLYS) | 13.0 | $158M | 5.9M | 26.98 |
|
|
| Septerna (SEPN) | 8.7 | $106M | 3.1M | 33.49 |
|
|
| Alamar Biosciences Common Stock | 5.5 | $67M | NEW | 2.5M | 27.09 |
|
| Neurogene (NGNE) | 4.4 | $54M | 1.7M | 31.45 |
|
|
| Kalaris Therapeutics (KLRS) | 4.3 | $52M | 13M | 4.07 |
|
|
| Spyglass Pharma Com Shs (SGP) | 3.9 | $47M | 2.1M | 22.26 |
|
|
| Sutro Biopharma Com Shs (STRO) | 2.9 | $35M | 1.1M | 33.20 |
|
|
| Inventiva Sa Ads (IVA) | 2.0 | $24M | +21% | 6.3M | 3.78 |
|
| Jade Biosciences Com New (JBIO) | 1.3 | $16M | -24% | 736k | 22.22 |
|
| Parabilis Medicines | 1.3 | $15M | NEW | 556k | 27.37 |
|
| Vtv Therapeutics Cl A New (VTVT) | 0.9 | $11M | 299k | 37.65 |
|
|
| Aquestive Therapeutics (AQST) | 0.9 | $10M | 2.5M | 4.16 |
|
|
| Nkarta (NKTX) | 0.8 | $9.9M | 3.5M | 2.83 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.8 | $9.3M | NEW | 955k | 9.70 |
|
| Rani Therapeutics Hldgs Com Cl A (RANI) | 0.6 | $7.9M | +21% | 10M | 0.76 |
|
| Agomab Therapeutics Nv Sponsored Ads (AGMB) | 0.6 | $7.8M | 600k | 12.98 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.6 | $7.3M | -2% | 55k | 133.26 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.5 | $6.5M | -23% | 1.4M | 4.67 |
|
| Eloxx Pharmaceuticals Com New | 0.5 | $5.6M | NEW | 400k | 13.88 |
|
| Coherus Biosciences (CHRS) | 0.4 | $4.8M | 3.4M | 1.40 |
|
|
| Upstream Bio (UPB) | 0.2 | $2.4M | -51% | 354k | 6.92 |
|
| Gossamer Bio (GOSS) | 0.1 | $1.2M | 7.2M | 0.16 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2026 Q2 filed Aug. 14, 2026
- Samsara BioCapital 2026 Q1 filed May 15, 2026
- Samsara BioCapital 2025 Q4 filed Feb. 17, 2026
- Samsara BioCapital 2025 Q3 filed Nov. 14, 2025
- Samsara BioCapital 2025 Q2 filed Aug. 14, 2025
- Samsara BioCapital 2025 Q1 filed May 15, 2025
- Samsara BioCapital 2024 Q4 filed Feb. 14, 2025
- Samsara BioCapital 2024 Q3 filed Nov. 14, 2024
- Samsara BioCapital 2024 Q2 filed Aug. 14, 2024
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023